These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16898269)

  • 1. Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Inoue K; Mori K; Fujii H; Mano H; Odgerel T; Furukawa Y
    Oncol Res; 2006; 16(2):85-95. PubMed ID: 16898269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro.
    Kano Y; Tanaka M; Akutsu M; Mori K; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1129-37. PubMed ID: 19306094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y
    Cancer Chemother Pharmacol; 1996; 37(6):525-30. PubMed ID: 8612305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
    Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
    Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
    Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Ando J; Matsui J; Suzuki K; Ikeda T; Inoue Y; Adachi K
    Br J Cancer; 1996 Sep; 74(5):704-10. PubMed ID: 8795571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Mori K; Yazawa Y; Tsunoda S
    Cancer Chemother Pharmacol; 1999; 44(5):381-8. PubMed ID: 10501911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro.
    Bischof M; Weber KJ; Blatter J; Wannenmacher M; Latz D
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1381-8. PubMed ID: 11955753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
    Li T; Ling YH; Goldman ID; Perez-Soler R
    Clin Cancer Res; 2007 Jun; 13(11):3413-22. PubMed ID: 17545550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L
    Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent interactions between raltitrexed and cisplatin in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S
    Jpn J Cancer Res; 2000 Apr; 91(4):424-32. PubMed ID: 10804291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
    Vandermeers F; Hubert P; Delvenne P; Mascaux C; Grigoriu B; Burny A; Scherpereel A; Willems L
    Clin Cancer Res; 2009 Apr; 15(8):2818-28. PubMed ID: 19351772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Mori K; Suzuki K; Adachi KI
    Cancer Chemother Pharmacol; 1998; 42(2):91-8. PubMed ID: 9654107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.
    Palumbo C; Battisti S; Carbone D; Albonici L; Alimandi M; Bei R; Modesti A
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):893-901. PubMed ID: 17922127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
    Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
    Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data.
    Zinner RG; Herbst RS
    Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S67-74. PubMed ID: 15117428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.
    Sigmond J; Backus HH; Wouters D; Temmink OH; Jansen G; Peters GJ
    Biochem Pharmacol; 2003 Aug; 66(3):431-8. PubMed ID: 12907242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.